Key terms

About AKRO

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AKRO news

Mar 12 9:44am ET JPMorgan SMid cap biotech analyst to hold analyst/industry conference call by TipRanks Mar 08 7:55am ET Akero Therapeutics’ Strong Trial Results and Market Positioning Justify Buy Rating by TipRanks Mar 06 1:58pm ET 89bio price target raised to $37 from $29 at Evercore ISI by TipRanks Mar 06 11:12am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 05 9:16pm ET Akero Therapeutics 11M share Secondary priced at $29.00 by TipRanks Mar 05 6:30am ET Analysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO) by TipRanks Mar 05 6:11am ET Akero Therapeutics price target raised to $50 from $43 at H.C. Wainwright by TipRanks Mar 04 4:25pm ET Akero Therapeutics announces $300M common stock offering by TipRanks Mar 04 12:55pm ET Akero Therapeutics: Promising Phase IIb Results Propel Strong Buy Rating by TipRanks Mar 04 12:51pm ET Akero Therapeutics price target raised to $50 from $35 at Jefferies by TipRanks Mar 04 12:50pm ET Akero Therapeutics price target raised to $50 from $36 at Evercore ISI by TipRanks Mar 04 12:45pm ET Akero upside capped on bone mineral density questions, says Cantor by TipRanks Mar 04 12:10pm ET Akero 96-week update ‘posiitve’ for 89Bio, says Raymond James by TipRanks Mar 04 7:50am ET Akero Therapeutics to host conference call by TipRanks Mar 04 6:03am ET Akero Therapeutics reports results from Phase 2B HARMONY study by TipRanks Mar 04 4:55am ET Akero Therapeutics to host conference call by TipRanks Mar 04 4:55am ET Akero Therapeutics to host conference call by TipRanks Mar 03 10:43pm ET Akero Therapeutics to host conference call by TipRanks Mar 01 12:40pm ET Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Akero Therapeutics (AKRO) by TipRanks Mar 01 12:29pm ET Akero Therapeutics price target raised to $43 from $40 at H.C. Wainwright by TipRanks Feb 29 4:15pm ET Akero Therapeutics’ Buy Rating Affirmed on Efruxifermin’s Promise for NASH Treatment by TipRanks Feb 29 7:08am ET Akero Therapeutics reports Q4 EPS (99c), consensus (86c) by TipRanks Feb 26 12:02pm ET Madrigal opportunity in MASH remains after Boehringer data, says UBS by TipRanks Feb 09 11:12am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 01 1:10pm ET Cantor biotech/biopharma analysts to hold analyst/industry conference call by TipRanks Jan 31 4:55am ET Akero Therapeutics management to meet with Cantor Fitzgerald by TipRanks Jan 25 10:46am ET Akero Therapeutics management to meet with Cantor Fitzgerald by TipRanks Dec 20 4:29am ET 3 Best Stocks to Buy Now, 12/20/2023, According to Top Analysts by TipRanks Dec 19 11:15am ET Akero Therapeutics’ Progress in Metabolic Liver Disease Treatments Prompts Buy Rating by TipRanks
Apr 14 11:16am ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO by Newsfile Apr 06 1:16pm ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO by Newsfile

AKRO Financials

1-year income & revenue

Key terms

AKRO Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AKRO Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming